

Hikma Pharmaceuticals: how our three businesses work together to improve health

London, 31 July 2024 – For over four decades, Hikma Pharmaceuticals has been at the forefront of providing high-quality, affordable medicines to patients across the US, MENA, and Europe. Our growth is driven by our three world-class businesses: Injectables, Branded, and Generics, each crucial in ensuring patient access to the treatments they need. The synergy between these businesses allows us to leverage our global expertise to improve local health outcomes.

Our purpose-driven strategy enables us to address growing healthcare needs across our markets. Through manufacturing excellence and our commitment to quality - our key differentiators - as well as continuous investment in R&D and strong commercial capabilities, we are delivering a diverse portfolio of high-quality, affordable medicines that meet both current and future market demands.

Injectables, our largest business, manufactures and supplies generic injectable medicines to hospitals across North America, Europe and MENA. It is distinguished by its extensive portfolio, high-quality manufacturing and strong commercial relationships. In the US, we are a top-three supplier of generic injectables¹ with a large and growing product portfolio that has tripled to more than 160 products in just a decade, and we continue to expand. Our recent intent to acquire Xellia, adds a commercial portfolio and pipeline, a US-based manufacturing facility, and an R&D centre in Croatia, further strengthening this business.

In Europe, we have expanded through new offices in Spain and the UK, leveraging production capacity from Portugal, Italy, and Germany to meet the increasing demand and help address medicine shortages. In MENA, we've invested in new production sites in Algeria and Morocco, and plan to strengthen our manufacturing capabilities in Saudi Arabia, to improve access to locally produced, high-quality medicines.

Our Branded business supplies branded generics and in-licensed patented products across MENA. Today, Hikma is the second-largest pharmaceutical company by sales in the region², operating across 17 markets with 20 plants in six countries. We have rapidly developed our product portfolio to treat cancer and chronic illnesses, with 60% of our Branded portfolio for chronic conditions. With an experienced commercial team of approximately 2,000, we are the partner of choice in the MENA region. In 2023, we achieved a record year in deal signings, adding over 25 assets to our portfolio. Important partnerships, such as our agreements with Guardant Health for cancer diagnostics and Rakuten Medical for innovative cancer treatments, further demonstrate our commitment to improving access to medicine and bringing cutting-edge healthcare solutions to MENA.

Our Generics business supplies oral and other non-injectable generic and specialty products to the US retail market. We excel in differentiated technologies, including inhalation, nasal sprays and high containment capabilities. Currently, we are the largest supplier of nasal sprays in the US. With our strong team and the expertise brought in by new leadership, we aim to expand our portfolio, leverage our position as a market-leading domestic US manufacturer to establish new partnerships, and focus on maximising our R&D investments to improve and accelerate our product pipeline.

Our Columbus facility, known for its high-quality standards and agility, enables us to respond quickly to market shortages and opportunities. We're committed to maximising this facility's potential through expanding our portfolio, pursuing opportunities to diversify our product range, and leveraging our reputation to secure valuable contract manufacturing partnerships.

¹ IQVIA MAT April 2024, generic injectable volumes by eaches, excluding branded generics and Becton Dickinson

² IQVIA MIDAS Pharma Index MAT Feb-2024. Retail + Hospital. Excluding Milks and diagnostics. Excluding Lebanon



Injectables, Branded, and Generics form our three world-class businesses, creating a diversified model that empowers us to improve healthcare outcomes in our key markets. Underpinning each business is our broad product portfolio, robust manufacturing strength, and commitment to quality. With 29 manufacturing plants across the US, MENA, and Europe, and more under construction, we further differentiate ourselves from our peers.

By harnessing the strengths of each business, we deliver targeted solutions to meet regional needs while maintaining a global perspective on healthcare needs and innovation. Our success stems from our strong manufacturing principles, efficient plants, and a highly skilled team. As we continue our R&D investments, broaden our manufacturing capabilities, and expand into new markets, we are poised to improve lives on a global scale.

-- ENDS --

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/positive Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,100 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

©2024 Hikma Pharmaceuticals PLC. All rights reserved.

Forward-looking statements

Hikma cautions shareholders that any forward-looking statements or projections made by Hikma, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those risk factors described in the "Principal risks and uncertainties" section in Hikma's latest Annual Report. Where included, such statements have been made by or on behalf of Hikma in good faith based upon the knowledge and information available to the Directors on the date of this announcement. Accordingly, no assurance can be given that any particular expectation will be met and Hikma's shareholders are cautioned not to place undue reliance on any forward-looking statements. Other than in accordance with its legal or regulatory obligations (including under the UK Market Abuse Regulation and the UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), Hikma does not undertake to update any forward-looking statements contained in this announcement to reflect any changes in events, conditions or circumstances on which any such statement is based or to correct any inaccuracies which may become apparent in any such forward-looking statements.